dipivefrin has been researched along with Hyperemia in 3 studies
dipivefrin: used in treatment of both primary & open angle glaucoma; RN given refers to (+-)-isomer
dipivefrin : The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.
Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect on intraocular pressure (IOP) and aqueous flare of topical applications of latanoprost and dipivefrin alone or combined." | 9.08 | Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. ( Alm, A; Mäepea, O; Widengård, I, 1998) |
| "To investigate the effect on intraocular pressure (IOP) and aqueous flare of topical applications of latanoprost and dipivefrin alone or combined." | 5.08 | Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. ( Alm, A; Mäepea, O; Widengård, I, 1998) |
| "Dipivefrin hydrochloride is a lipophilic prodrug for epinephrine hydrochloride, allowing lower concentration of the drug to achieve the same intraocular pressure lowering effect and having also less harmful effects than epinephrine hydrochloride." | 1.29 | Corneal vascularization and opacification during long-term use of dipivefrin. ( Hakala, T; Helin, H; Krootila, K; Salminen, L, 1995) |
| "1%) developed adverse external ocular side effects severe enough to require that the drug be discontinued." | 1.26 | External ocular toxicity of dipivalyl epinephrine. ( Leibowitz, HM; Theodore, J, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salminen, L | 1 |
| Krootila, K | 1 |
| Helin, H | 1 |
| Hakala, T | 1 |
| Widengård, I | 1 |
| Mäepea, O | 1 |
| Alm, A | 1 |
| Theodore, J | 1 |
| Leibowitz, HM | 1 |
1 trial available for dipivefrin and Hyperemia
| Article | Year |
|---|---|
Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability.
Topics: Adrenergic Agonists; Aged; Blood-Aqueous Barrier; Conjunctival Diseases; Drug Administration Schedul | 1998 |
2 other studies available for dipivefrin and Hyperemia
| Article | Year |
|---|---|
Corneal vascularization and opacification during long-term use of dipivefrin.
Topics: Blepharitis; Conjunctival Diseases; Corneal Neovascularization; Corneal Opacity; Epinephrine; Female | 1995 |
External ocular toxicity of dipivalyl epinephrine.
Topics: Administration, Topical; Aged; Conjunctiva; Conjunctivitis; Drug Tolerance; Epinephrine; Eye Disease | 1979 |